Medicare Enrolled
Dr. Uriel Sandkovsky, MD, MS
Internal Medicine · Dallas, TX
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Sandkovsky from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Sandkovsky?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Sandkovsky
Dr. Uriel Sandkovsky is an internal medicine specialist in Dallas, TX, with 17 years of NPI registration. Based on federal Medicare data, Dr. Sandkovsky performed 17,158 Medicare services in 2023. These records do not provide a deduplicated patient total.
Between the years covered by Open Payments, Dr. Sandkovsky received a total of $290,387 from 42 pharmaceutical and/or device companies across 857 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Sandkovsky is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 17 years of NPI registration
▲ Top 2% volume in TX
$290,387 industry payments
Medicare Practice Summary — 2023
Medicare Utilization ↗17,158
Medicare services
Top 2% in TX for internal medicine
Not available
Unique patients (not deduplicated)
$30
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Denosumab injection (Prolia/Xgeva) | 13,500 | $18 | $50 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
1,103 | $93 | $289 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
776 | $62 | $202 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
420 | $79 | $279 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
339 | $50 | $394 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
289 | $10 | $59 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
268 | $137 | $546 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
190 | $6 | $41 |
| Ertapenem sodium injection, 500 mg An injection of ertapenem sodium, an antibiotic medication, administered at a dose of 500 mg. |
75 | $10 | $79 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
67 | $48 | $185 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
40 | $113 | $425 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
25 | $130 | $377 |
| Home health agency supervision, complex multidisciplinary care Supervision by a physician or allowed practitioner for a patient receiving Medicare-covered services from a participating home health agency. This involves complex and multidisciplinary care modalities, with the patient not present during the supervision. |
23 | $83 | $303 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
22 | $103 | $372 |
| Infusion tube insertion with imaging guidance A radiologist inserts an infusion tube into the body while using imaging guidance to ensure proper placement and reviews the procedure. |
21 | $283 | $1,225 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
2.1% high complexity
81.9% medium
16.0% routine
Industry Payment Transparency
Open Payments through 2024 ↗$290,387
Total received (2018-2024)
Avg $41,484/year across 7 years
Top 1% in TX for internal medicine
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
42
Companies
857
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →
Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$108,914
2023
$87,011
2022
$41,707
2021
$21,619
2020
$12,855
2019
$17,507
2018
$774
Payments by company (2024)
AIMMUNE THERAPEUTICS, INC.
$52,393
Shionogi Inc
$20,707
PFIZER INC.
$20,625
Paratek Pharmaceuticals, Inc.
$7,271
PFIZER INTERNATIONAL LLC
$3,500
ViiV Healthcare Company
$2,621
Gilead Sciences, Inc.
$407
Merck Sharp & Dohme LLC
$273
Insmed, Inc.
$211
ABBVIE INC.
$145
Astellas Pharma US Inc
$142
Napo Pharmaceuticals Inc
$132
EMD Serono, Inc.
$107
Takeda Pharmaceuticals U.S.A., Inc.
$72
La Jolla Pharmaceutical Company
$66
Ferring Pharmaceuticals Inc.
$63
Octapharma USA, Inc.
$59
HOSPIRA, INC.
$53
Melinta Therapeutics, LLC
$31
Amgen Inc.
$18
Theratechnologies Inc.
$18
Top 3 companies account for 86.1% of 2024 payments
All-time payments by company (2018-2024) ›
Shionogi Inc
$79,992
PFIZER INC.
$64,568
AIMMUNE THERAPEUTICS, INC.
$52,453
ViiV Healthcare Company
$40,528
Paratek Pharmaceuticals, Inc.
$36,813
TETRAPHASE PHARMACEUTICALS, INC.
$4,587
PFIZER INTERNATIONAL LLC
$3,500
Gilead Sciences, Inc.
$1,010
Insmed, Inc.
$961
Astellas Pharma US Inc
$799
Merck Sharp & Dohme LLC
$618
EMD Serono, Inc.
$538
Napo Pharmaceuticals Inc
$445
Novocure Inc.
$413
Janssen Biotech, Inc.
$337
Cumberland Pharmaceuticals, Inc.
$315
Saol Therapeutics Inc.
$290
ABBVIE INC.
$279
Merck Sharp & Dohme Corporation
$265
La Jolla Pharmaceutical Company
$192
Ferring Pharmaceuticals Inc.
$186
Theratechnologies Inc.
$156
Takeda Pharmaceuticals U.S.A., Inc.
$152
AbbVie Inc.
$140
Janssen Products, LP
$125
MAYNE PHARMA INC.
$104
Amgen Inc.
$96
Octapharma USA, Inc.
$82
Melinta Therapeutics, LLC
$73
Mayne Pharma Inc.
$56
HOSPIRA, INC.
$53
Allergan Inc.
$43
Melinta Therapeutics, Inc.
$30
VBI Vaccines (Delaware) Inc.
$29
KCI USA, Inc.
$26
Novartis Pharmaceuticals Corporation
$24
Eurofins Viracor, Inc.
$24
Amarin Pharma Inc.
$23
Grifols USA, LLC
$21
Genentech USA, Inc.
$19
Nabriva Therapeutics, plc
$11
Dynavax Technologies Corporation
$11
Top 3 companies account for 67.8% of all-time payments
Associated products mentioned in payments ›
ACTIMMUNE · AMBISOME · APRETUDE · AVYCAZ · Arikayce · Baxdela · Biktarvy · CABENUVA · CRESEMBA · Cresemba · DALVANCE · DELSTRIGO · DIFICID · DORYX · DOVATO · EGRIFTA · ELIQUIS · EVENITY · Fetroja · GATTEX · GIAPREZA · Heplisav-B · ISENTRESS · JULUCA · Kimyrsa · LIVTENCITY · MYCAMINE · Mytesi · NOXAFIL · NUZYRA · OCTAGAM IMMUNE GLOBULIN (HUMAN) · PANZYGA · PAXLOVID · PIFELTRO · PREVENA · PREVNAR - 13 · PREVNAR 13 · PREVYMIS · PREZCOBIX · PreHevbrio · REBYOTA · RUKOBIA · Rezzayo · SEROSTIM · SYMTUZA · Serostim · Symtuza · TEFLARO · TIVICAY · TRIUMEQ · TROGARZO · VAC VERAFLO · VIBATIV · VOWST · Vabomere · Vascepa · Vibativ · XERAVA · Xembify · Xenleta · Xerava · Xofluza · ZENPEP · ZERBAXA
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Geographic Context
Internal medicine physicians in nearby ZIP areas
2,266
County median income
$74,149
Nearest hospital to ZIP centroid (approximate)
PARKLAND HEALTH & HOSPITAL SYSTEM
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | NPPES snapshot; verify current record |
| Medicare Enrollment | ✓ PECOS | PECOS snapshot |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not included | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Sandkovsky is a mixed practice specialist, with above-average Medicare volume (top 2% in TX), with 17 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Sandkovsky experienced with denosumab injection (prolia/xgeva)?
Based on Medicare claims data, Dr. Sandkovsky performed 13,500 denosumab injection (prolia/xgeva) services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Sandkovsky receive payments from pharmaceutical companies?
Yes. Dr. Sandkovsky received a total of $290,387 from 42 companies across 857 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Sandkovsky's costs compare to other internal medicine physicians in Dallas?
Dr. Sandkovsky's average Medicare payment per service is $30. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Sandkovsky) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
Explore related providers
Same specialty & city
Internal Medicine Physicians in Dallas
Browse internal medicine physicians in Dallas ranked by procedure volume and transparency data.
Highest volume
Top Internal Medicine Physicians in TX
Internal medicine physicians ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Internal Medicine Physicians in TX
Which TX internal medicine physicians receive the most from drug and device companies.
By company
Shionogi Inc Payments to Doctors
See all physicians who received payments from Shionogi Inc.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
By company
AIMMUNE THERAPEUTICS, INC. Payments to Doctors
See all physicians who received payments from AIMMUNE THERAPEUTICS, INC.
About this page
This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology